Search

everythinglearnresearchcommunity

for

Search:↓

A person with Alopecia Areata on their beard is using CB-03-01 and oral minoxidil for treatment. Some users question the effectiveness of CB-03-01 for beard hair, suggesting that minoxidil alone may be responsible for any observed hair growth.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Update on HMI-115 clinical trial expected in July or August.

GHK-Cu injections led to unexpected temple hair growth for someone who had been using minoxidil and finasteride for over a decade. The user plans to continue using GHK-Cu and experiment with a DIY AHK-Cu serum.

The conversation discusses using liquid cetirizine as a topical treatment for hair loss. It mentions Minoxidil, finasteride, and RU58841 as other treatments.

Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

Cbum's hair transplant is criticized for looking unnatural and not blending well, with some suggesting better results were expected given his resources. Discussions also cover the effects of steroids and finasteride on hair loss and muscle growth.

The conversation discusses biannual SCUBE3 injections and microneedling as treatments for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

SCUBE3 is a potential hair loss treatment that people are hopeful about. It may provide a solution without the side effects of finasteride.

Treatments for hair loss, specifically the use of minoxidil, finasteride and RU58841. Replies to this post suggest that users should share relevant information publicly rather than through direct messages.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.

A gel of keratin microspheres promotes hair follicle growth, showing similar effectiveness to minoxidil in mice. The treatment activates hair growth pathways and reduces inflammation, with potential applications in drug delivery for hair-related disorders.

User tries dermapen for hair loss and plans to use non-mainstream topicals like c60, ghk-cu, and ptd-dbm with valproic acid. They also use a head massager and modified LLLT belt for additional treatment.

Caffeine intake may increase DHT levels, but its impact on hair loss is minimal compared to genetic factors. Excessive caffeine can cause health issues, and its effects on hair loss are not directly applicable to humans based on rat studies.

The conversation is about a user who experienced negative side effects and poor sleep after using an impure hair loss treatment 'CB' from Wuhan Hengheda Pharm, which did not offer a refund or proper customer service. The user had the product tested, confirming its impurity.

The conversation is about seeking updates on the hair loss treatment RCH-01, specifically its next phase and any news from Shiseido. The user recalls someone being in contact with a researcher or company representative.

Hair loss treatments RU55841, CB-03-01, and Eucapil were discussed, with concerns about needing increased dosages over time and potential side effects. A user suggested that CB's results could be due to various factors and that combining it with finasteride might slow down any upregulation.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

A new potential hair loss treatment called HMI-115, and the cost of this treatment which may be expensive due to production costs but could be competitive with other treatments such as hair transplants.

The conversation is about experiences with GHK-Cu Copper and AHK-Cu Copper for hair regrowth and thickening. One user expressed skepticism about its effectiveness.

PP405 from Everychem is likely fake and potentially harmful, with concerns about its stability and the risk of using the wrong MPC inhibitor, which could damage hair follicles. The real PP405 was studied under strict conditions, and DIY attempts are discouraged due to unknown formulation and quality control.

Stevia microneedles increased minoxidil absorption and hair growth in mice. The conversation humorously questions the applicability of these results to humans.

The conversation discusses concerns about Scube3's effectiveness and potential cancer link. It questions whether Scube3 can regrow hair and how well it works according to researchers.

Stem cell treatment research shows promise in reversing hair loss in mice, but it's likely 10 years away and expensive. Current recommended treatments include minoxidil, finasteride, and hair transplants.

The user is concerned about the toxicity of a homemade topical solution of minoxidil and finasteride to their new kitten and is considering replacing minoxidil with stemoxydine. Other users suggest using oral treatments, keeping the solution away from the cat, and ensuring proper hygiene.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

Users discussed using GHK-Cu and AHK-Cu peptides with microneedling for hair loss, noting some small changes after 7-8 weeks. They mentioned continued shedding but no widening of the part.